Table 1 Demographic and clinical data of GIST patients of sub-cohort I (<50 years, “young” ) and sub-cohort II (≥50 years, “old” )
From: Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST)
Parameter | Sub-cohort I (n = 87) | Sub-cohort II (n = 125) | |||
|---|---|---|---|---|---|
<50 yr(“young”) | ≥50 yr(“old”) | ||||
Age | |||||
median (range, yr) | 41.7 (14.9;49.9) | 68.2 (50.9; 94.1) | |||
Sex | n | % | n | % | |
female | 48 | 55.2 | 68 | 54.4 | |
male | 39 | 44.8 | 57 | 45.6 | |
Localization | |||||
stomach | 43 | 50.6 | 79 | 64.2 | |
small intestine | 29 | 34.1 | 35 | 28.5 | |
colorectum | 5 | 5.9 | 2 | 1.6 | |
esophagus | 1 | 1.2 | 1 | 0.8 | |
EGIST | 3 | 3.5 | 3 | 2.4 | |
n.d. | 4 | 4.7 | 3 | 2.4 | |
Tumor size | |||||
median (range, cm) | 5.5 (1.2; 27.0) | 4.5 (0.4;40.0) | |||
Risk according to Fletcher et al. [23] | n | % | n | % | |
high | 29 | 41.4 | 35 | 31.8 | |
intermediate | 15 | 21.4 | 25 | 22.7 | |
low | 17 | 24.3 | 31 | 28.2 | |
very Low | 9 | 12.9 | 19 | 17.3 | |
Risk according to Miettinen et al. [11] | |||||
high | 22 | 33.3 | 30 | 29.7 | |
intermediate | 10 | 15.2 | 7 | 6.9 | |
low | 25 | 37.9 | 43 | 42.6 | |
very Low | 9 | 13.6 | 21 | 20.8 | |
Histological subtype | |||||
spindle cell | 63 | 85.1 | 98 | 89.1 | |
Epithelioid/mixed | 11 | 14.9 | 12 | 10.9 | |
Immunohistochemistry | |||||
KIT pos | 74 | 94.9 | 115 | 98.3 | |
KIT neg | 4 | 5.1 | 2 | 1.7 | |
CD34 pos | 48 | 82.8 | 84 | 84.0 | |
CD34 neg | 10 | 17.2 | 16 | 16.0 | |
S100 pos | 11 | 25.6 | 1 | 1.4 | |
S100 neg | 32 | 74.4 | 68 | 98.6 | |
Clinical data | |||||
Metastasis atdiagnosis | 9 | 10.3 | 16 | 12.8 | |
Secondneoplasia | 11 | 15.5 | 45 | 38.8 | |
R0resection | 81 | 93.1 | 112 | 89.6 | |
Tumor debulking | 4 | 4.6 | 7 | 7.2 | |
Imatinib use | 24 | 27.6 | 27 | 21.6 | |
Recurrenceof disease and/ormetastasis | |||||
yes | 21 | 25.9 | 32 | 29.6 | |
Follow up time | |||||
mean (yr, ±SD) | 4.90 (3.39) | 5.65 (4.55) | |||
median (range, yr) | 4.28 (0.59;16.31) | 4.57 (0.56;21.33) | |||
deceased | 9 | 10.3 | 40 | 32.0 | |
alive | 78 | 89.7 | 85 | 68.0 | |
tumor-relateddeath | 5 | 5.7 | 20 | 16.0 | |
Survival rate | % (n) | % (n) | |||
DSS (yr1/yr3/yr5) | 98.5 (64)/96.6 (49)/96.6 (34) | 96.2 (93)/87.0 (67)/81.2 (44) | |||
DFS (yr1/yr3/yr5) | 88.4 (57)/81.2 (41)/78.8 (29) | 79.0 (74)/74.2 (55)/69.9 (36) | |||
OS (yr1/yr3/yr5) | 98.5 (64)/93.2 (49)/91.2 (34) | 90.8 (93)/77.4 (67)/67.0 (44) | |||
Syndromal disease | 3xNF1 | 3.4% | 3x NF1 | 2.4% | |
1x Carney | 1% | ||||